Purple Biotech (PPBT) Cash & Equivalents (2014 - 2026)

Purple Biotech (PPBT) has reported Cash & Equivalents for 13 consecutive years, with $5.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 3.55% year-over-year to $5.6 million; the TTM figure through Mar 2026 stood at $5.6 million (down 3.55% YoY), while the FY2025 annual figure was $8.7 million, up 17.78% from the prior year.
• Cash & Equivalents fell to $5.6 million in Q1 2026 per PPBT's latest filing, from $8.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $23.5 million in Q1 2022 and bottomed at $4.7 million in Q2 2025.
• Historically, Cash & Equivalents has averaged $11.5 million across 5 years, with a median of $10.0 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents soared 130.87% — and 2024, when it sank 64.0%.
• Purple Biotech's Cash & Equivalents stood at $15.0 million in 2022, then fell by 3.6% to $14.5 million in 2023, then slumped by 48.92% to $7.4 million in 2024, then climbed by 17.78% to $8.7 million in 2025, then tumbled by 36.14% to $5.6 million in 2026.
• Business Quant data shows PPBT's Cash & Equivalents at $5.6 million in Q1 2026, $8.7 million in Q4 2025, and $9.6 million in Q3 2025.